Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML

Date

29 Sep 2019

Session

ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Presenters

Lars Bullinger

Authors

L. Bullinger

Author affiliations

  • Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
More

Resources

Resources from the same session

Are FLT3 Mutated AML a special entity?

Presenter: Gert Ossenkoppele

Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Resources:

Presentation

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings